Boston Therapeutics has a new tablet PAZ320 designed to reduce a person's sugar intake by 40%. CEO Dr. David Platt believes the tablet will eventually be approved for non-diabetic patients looking to cut back on the copious amounts of sugar prevalent in many processed foods. The company also makes an intravenous drug that will help diabetic foot ulcers heal more quickly.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

More from Video

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Video: This Startup Connects Buyers and Sellers of Legal Marijuana

Video: This Startup Connects Buyers and Sellers of Legal Marijuana

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: If You're Concerned About Visa's Run, Check Out Global Payments

Jim Cramer: If You're Concerned About Visa's Run, Check Out Global Payments

60 Seconds: What the Heck is GDPR?

60 Seconds: What the Heck is GDPR?